Nursing practice questions with comprehensive rationales
NurseDive Free Nursing Practice Question
The nurse is designing interventions when using cognitive enhancers for clients with Alzheimer’s disease. Which statement is important to include?
A. The use of cognitive enhancers depends on the severity of the symptoms experienced by the client
Cognitive enhancers like donepezil or memantine are prescribed based on Alzheimer’s disease stage. Cholinesterase inhibitors are effective in mild-to-moderate stages, enhancing acetylcholine levels to improve cognition. Memantine, an NMDA receptor antagonist, is used in moderate-to-severe stages to regulate glutamate activity, slowing cognitive decline. This statement is accurate, as treatment is tailored to symptom severity.
B. These drugs can be used in all stages of Alzheimer’s disease
Cognitive enhancers are not equally effective in all Alzheimer’s stages. Cholinesterase inhibitors benefit mild-to-moderate cases, while memantine is used in severe stages. Their efficacy diminishes in advanced disease due to extensive neuronal loss, making this statement inaccurate, as stage-specific prescribing is critical for therapeutic benefit.
C. Medications for anxiety and depression are not helpful once cognitive enhancers are used
Medications for anxiety and depression, like SSRIs, remain helpful in Alzheimer’s to manage behavioral symptoms, even with cognitive enhancers. These drugs address mood disorders, which often coexist, improving quality of life. This statement is inaccurate, as combination therapy is common and beneficial in managing neuropsychiatric symptoms.
D. Cognitive enhancers are also used for seizure management as well
Cognitive enhancers are not used for seizure management. Anticonvulsants like levetiracetam manage seizures, which may occur in Alzheimer’s due to neuronal excitability. Cognitive enhancers target cognitive decline via cholinergic or glutamatergic pathways, not seizure control, making this statement inaccurate and unrelated to their pharmacological role.
This question is an excerpt from Nurse Dive's nursing test bank - Pathophamacology Proctored Exam (Examplify). Take the full exam now
Full Explanation
Choice A reason: Cognitive enhancers like donepezil or memantine are prescribed based on Alzheimer’s disease stage. Cholinesterase inhibitors are effective in mild-to-moderate stages, enhancing acetylcholine levels to improve cognition. Memantine, an NMDA receptor antagonist, is used in moderate-to-severe stages to regulate glutamate activity, slowing cognitive decline. This statement is accurate, as treatment is tailored to symptom severity.
Choice B reason: Cognitive enhancers are not equally effective in all Alzheimer’s stages. Cholinesterase inhibitors benefit mild-to-moderate cases, while memantine is used in severe stages. Their efficacy diminishes in advanced disease due to extensive neuronal loss, making this statement inaccurate, as stage-specific prescribing is critical for therapeutic benefit.
Choice C reason: Medications for anxiety and depression, like SSRIs, remain helpful in Alzheimer’s to manage behavioral symptoms, even with cognitive enhancers. These drugs address mood disorders, which often coexist, improving quality of life. This statement is inaccurate, as combination therapy is common and beneficial in managing neuropsychiatric symptoms.
Choice D reason: Cognitive enhancers are not used for seizure management. Anticonvulsants like levetiracetam manage seizures, which may occur in Alzheimer’s due to neuronal excitability. Cognitive enhancers target cognitive decline via cholinergic or glutamatergic pathways, not seizure control, making this statement inaccurate and unrelated to their pharmacological role.
Similar Questions
A client is viewing X-rays of a healing bone fracture and asks the nurse if the bone will ever be ‘normal’ again. Based on the nurse’s knowledge of bone healing, what is the best response?
A. The bone will be more ‘normal’ when there is inflammation and hematoma surrounding the fracture site
Inflammation and hematoma formation occur immediately after a fracture, initiating healing by recruiting immune cells and growth factors. However, this stage does not restore ‘normal’ bone structure, as it involves soft tissue response, not bone remodeling. This statement is inaccurate, as the bone remains structurally abnormal during this early phase.
B. The bone will be more ‘normal’ when callus formation occurs
Callus formation, occurring 2-6 weeks post-fracture, involves soft and hard callus bridging the fracture. While critical, it represents a temporary, weaker structure, not ‘normal’ bone. Osteoblasts form a cartilaginous matrix, but full strength and normal bone architecture require further remodeling, making this statement less accurate.
C. The bone will be more like ‘normal’ when bone-forming cells absorb the callus into woven bone
Woven bone formation, where osteoblasts convert callus into disorganized woven bone, marks progression toward normal bone structure. This bone is later remodeled by osteoclasts and osteoblasts into lamellar bone, restoring strength and architecture. This statement is accurate, as woven bone formation approaches ‘normal’ bone structure during healing.
D. The bone will be more normal when there is a proliferation of osteoclasts at the site
Osteoclast proliferation resorbs bone during remodeling but does not directly restore ‘normal’ bone. Excessive osteoclast activity could weaken the bone. Osteoblasts, not osteoclasts, drive the formation of woven and lamellar bone, making this statement inaccurate, as osteoclasts support remodeling, not normalization, of bone structure.
Full Explanation
Choice A reason: Inflammation and hematoma formation occur immediately after a fracture, initiating healing by recruiting immune cells and growth factors. However, this stage does not restore ‘normal’ bone structure, as it involves soft tissue response, not bone remodeling. This statement is inaccurate, as the bone remains structurally abnormal during this early phase.
Choice B reason: Callus formation, occurring 2-6 weeks post-fracture, involves soft and hard callus bridging the fracture. While critical, it represents a temporary, weaker structure, not ‘normal’ bone. Osteoblasts form a cartilaginous matrix, but full strength and normal bone architecture require further remodeling, making this statement less accurate.
Choice C reason: Woven bone formation, where osteoblasts convert callus into disorganized woven bone, marks progression toward normal bone structure. This bone is later remodeled by osteoclasts and osteoblasts into lamellar bone, restoring strength and architecture. This statement is accurate, as woven bone formation approaches ‘normal’ bone structure during healing.
Choice D reason: Osteoclast proliferation resorbs bone during remodeling but does not directly restore ‘normal’ bone. Excessive osteoclast activity could weaken the bone. Osteoblasts, not osteoclasts, drive the formation of woven and lamellar bone, making this statement inaccurate, as osteoclasts support remodeling, not normalization, of bone structure.
Which statement is an important nursing implication in the management of a client who is taking trimethoprim/sulfamethoxazole for a urinary tract infection?
A. Extended periods outside in sunshine are important for vitamin D for this client
Trimethoprim/sulfamethoxazole does not require extended sun exposure. In fact, it causes photosensitivity, increasing sunburn risk, so patients should avoid prolonged sunlight. Vitamin D synthesis is unrelated to this antibiotic’s mechanism or side effects, making this statement inaccurate and potentially harmful for patient safety.
B. Clients should be told to expect brown urine while taking this medication
Trimethoprim/sulfamethoxazole does not typically cause brown urine. Brown urine may indicate hematuria or other conditions, but it is not a common side effect of this drug. The medication may cause gastrointestinal upset or rash, but urine discoloration is not expected, making this statement inaccurate.
C. Follow-up with the Health Care Provider is unnecessary
Follow-up with a healthcare provider is necessary to ensure UTI resolution and monitor for side effects like rash, renal impairment, or rare hematologic effects. This statement is inaccurate, as lack of follow-up could miss treatment failure or complications, undermining effective management of the infection.
D. Client should be monitored for anemia
Trimethoprim/sulfamethoxazole can cause bone marrow suppression, leading to anemia, particularly in patients with folate deficiency or prolonged use. Monitoring complete blood counts is critical to detect hemolytic anemia or other hematologic toxicities, making this statement accurate and essential for safe patient management during treatment.
Full Explanation
Choice A reason: Trimethoprim/sulfamethoxazole does not require extended sun exposure. In fact, it causes photosensitivity, increasing sunburn risk, so patients should avoid prolonged sunlight. Vitamin D synthesis is unrelated to this antibiotic’s mechanism or side effects, making this statement inaccurate and potentially harmful for patient safety.
Choice B reason: Trimethoprim/sulfamethoxazole does not typically cause brown urine. Brown urine may indicate hematuria or other conditions, but it is not a common side effect of this drug. The medication may cause gastrointestinal upset or rash, but urine discoloration is not expected, making this statement inaccurate.
Choice C reason: Follow-up with a healthcare provider is necessary to ensure UTI resolution and monitor for side effects like rash, renal impairment, or rare hematologic effects. This statement is inaccurate, as lack of follow-up could miss treatment failure or complications, undermining effective management of the infection.
Choice D reason: Trimethoprim/sulfamethoxazole can cause bone marrow suppression, leading to anemia, particularly in patients with folate deficiency or prolonged use. Monitoring complete blood counts is critical to detect hemolytic anemia or other hematologic toxicities, making this statement accurate and essential for safe patient management during treatment.
A client admitted for injuries from a motor vehicle crash has a history of bipolar disorder for which he takes lithium. What is a major concern of the nurse?
A. Lithium toxicity is likely in the client’s treatment
Lithium toxicity is a concern but not inevitable. It occurs with levels above 1.5 mEq/L, often due to dehydration or drug interactions, common in trauma settings. However, routine monitoring of levels is a more immediate nursing priority than assuming toxicity, as early detection prevents severe outcomes like seizures or renal damage.
B. Lithium is completely metabolized by the liver so liver function tests are indicated
Lithium is primarily excreted by the kidneys, not metabolized by the liver. Liver function tests are not indicated for lithium monitoring, as it does not undergo hepatic metabolism. This statement is inaccurate, as renal function tests are critical to assess lithium clearance and prevent toxicity in trauma patients.
C. Lithium requirements increase with stress so additional lithium may be required
Stress does not directly increase lithium requirements. Trauma-related dehydration or renal impairment can elevate lithium levels, risking toxicity, but this is due to reduced clearance, not increased need. This statement is inaccurate, as dosing adjustments should be based on serum levels, not stress alone.
D. Lithium has a very narrow therapeutic range so lithium levels should be obtained
Lithium has a narrow therapeutic range (0.6-1.2 mEq/L), and trauma-related factors like dehydration or medications can alter levels, risking toxicity or subtherapeutic effects. Regular serum level monitoring is critical, especially in acute settings, to ensure safety and efficacy, making this statement accurate and a priority nursing concern.
Full Explanation
Choice A reason: Lithium toxicity is a concern but not inevitable. It occurs with levels above 1.5 mEq/L, often due to dehydration or drug interactions, common in trauma settings. However, routine monitoring of levels is a more immediate nursing priority than assuming toxicity, as early detection prevents severe outcomes like seizures or renal damage.
Choice B reason: Lithium is primarily excreted by the kidneys, not metabolized by the liver. Liver function tests are not indicated for lithium monitoring, as it does not undergo hepatic metabolism. This statement is inaccurate, as renal function tests are critical to assess lithium clearance and prevent toxicity in trauma patients.
Choice C reason: Stress does not directly increase lithium requirements. Trauma-related dehydration or renal impairment can elevate lithium levels, risking toxicity, but this is due to reduced clearance, not increased need. This statement is inaccurate, as dosing adjustments should be based on serum levels, not stress alone.
Choice D reason: Lithium has a narrow therapeutic range (0.6-1.2 mEq/L), and trauma-related factors like dehydration or medications can alter levels, risking toxicity or subtherapeutic effects. Regular serum level monitoring is critical, especially in acute settings, to ensure safety and efficacy, making this statement accurate and a priority nursing concern.